微小残存病変検査市場：技術、適応症、エンドユーザー別-2025～2030年の世界予測

微小残存病変検査市場は、2023年に18億3,000万米ドルと評価され、2024年には20億5,000万米ドルに達すると予測され、CAGR 12.36％で成長し、2030年には41億4,000万米ドルに達すると予測されています。

微小残存病変（MRD）検査とは、治療後に患者に残存する可能性のあるわずかな数のがん細胞を検出・測定するプロセスを指し、特に血液悪性腫瘍において、がんの再発リスクを評価するために極めて重要です。MRD検査の必要性は、治療効果に関するより深い洞察を提供し、予後評価に情報を提供し、個別化された治療戦略を導くその能力から生じています。用途は主に腫瘍学、特に白血病、リンパ腫、骨髄腫などの疾患に焦点を当て、患者がオーダーメイドの治療を受けられるようにし、臨床医が治療後により多くの情報に基づいた決定を下せるようにします。最終用途の範囲には、患者の転帰を向上させるためにMRD技術に投資する病院、診断ラボ、研究機関が多く含まれます。

市場洞察によると、MRD検査セグメントに影響を与える主要成長要因には、分子診断の技術的進歩、血液がんの有病率の増加、精密医療に対する意識の高まりと採用が含まれます。次世代シーケンシング（NGS）やポリメラーゼ連鎖反応（PCR）のような高感度で非侵襲的な技術の開発により、微小レベルの残存病変を検出する能力がさらに拡大しています。MRD検査の用途を血液学的なものから固形がんにまで拡大することで、潜在的な大きな機会が存在し、その市場規模は飛躍的に拡大する可能性があります。このような機会を活用するための推奨事項としては、標準化、検証済み、より安価なMRDアッセイの開発、技術革新を加速するためのバイオテクノロジー企業と研究機関の戦略的提携が挙げられます。

しかし、市場開拓は、MRD検査技術に関連する高コスト、新興国地域でのアクセス制限、複雑な結果を解釈する熟練者の必要性などの課題に直面しています。さらに、規制上のハードルやガイドラインの進化は、新しいMRD手法の採用を遅らせる可能性があります。成長と革新のためには、MRDデータ分析への人工知能と機械学習の統合に焦点を当てることで、結果の解釈を変革し、より正確でユーザーフレンドリーなものにすることができます。最終的に、MRD検査市場は急速に進化しており、主要な障壁に戦略的に対処すれば、かなりの成長の可能性があります。

市場力学：急速に進化する微小残存病変検査市場の主要な市場洞察を解明

微小残存病変検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 様々ながんに対する治療決定の精緻化の必要性
  • 世界人口における血液悪性腫瘍の有病率の上昇
• 市場抑制要因
  • MRD検査に伴う高コスト
• 市場機会
  • 個別化されたMRD検査技術の進化
  • 新しい微小残存病変検査法の継続的開発
• 市場課題
  • MRDの商業化に対する政府の厳しい規制

ポーターのファイブフォース：微小残存病変検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：微小残存病変検査市場における外部からの影響の把握

外部マクロ環境要因は、微小残存病変検査市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：微小残存病変検査市場における競合情勢の把握

微小残存病変検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：微小残存病変検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、微小残存病変検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：微小残存病変検査市場における成功への道筋を描く

微小残存病変検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • さまざまながんに対する治療決定の改善の必要性
    • 世界人口における造血悪性腫瘍の罹患率の上昇
  • 抑制要因
    • MRD検査に伴う高コスト
  • 機会
    • パーソナライズされたMRD検査技術の進化
    • 新しい微小残存病変検査メソッドの継続的な開発
  • 課題
    • MRDの商業化に対する厳しい政府規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 微小残存病変検査市場：技術別

• イントロダクション
• フローサイクロメトリー
• 次世代シーケンシング
• ポリメラーゼ連鎖反応

第7章 微小残存病変検査市場：適応症別

• イントロダクション
• 白血病
• リンパ腫
• 骨髄腫

第8章 微小残存病変検査市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• 診断ラボ
• 病院

第9章 南北アメリカの微小残存病変検査市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の微小残存病変検査市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの微小残存病変検査市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Adaptive BIoTechnologies Corporation
• Agilus Diagnostics Ltd.
• Amgen Inc.
• ARUP Laboratories
• AstraZeneca PLC
• Asuragen Inc. by Bio-Techne Corporation
• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Company
• C2I Genomics Inc.
• Cergentis B.V.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Genetron Holdings Limited
• GRAIL, LLC by Illumina, Inc.
• Guardant Health, Inc.
• Integrated DNA Technologies, Inc.
• Invivoscribe, Inc.
• Kite Pharma, Inc. by Gilead Sciences, Inc.
• Laboratory Corporation of America Holdings
• Mdxhealth BV
• MedGenome Inc
• Mission Bio, Inc.
• Myriad Genetics, Inc.
• Natera Inc.
• NeoGenomics Laboratories, Inc.
• OPKO Health, Inc.
• Quest Diagnostics incorporated
• Sysmex Corporation
• Veracyte, Inc.

LIST OF FIGURES

• FIGURE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET RESEARCH PROCESS
• FIGURE 2. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MINIMAL RESIDUAL DISEASE TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYCLOMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 30. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Minimal Residual Disease Testing Market was valued at USD 1.83 billion in 2023, expected to reach USD 2.05 billion in 2024, and is projected to grow at a CAGR of 12.36%, to USD 4.14 billion by 2030.

Minimal Residual Disease (MRD) testing refers to the process of detecting and measuring the small number of cancer cells that may remain in a patient after treatment, crucial for assessing the risk of cancer recurrence, particularly in hematologic malignancies. The necessity for MRD testing stems from its ability to provide deeper insights into treatment efficacy, inform prognostic evaluations, and guide personalized treatment strategies. Applications focus primarily within oncology, especially for conditions such as leukemia, lymphoma, and myeloma, ensuring that patients receive tailored care and enabling clinicians to make more informed decisions post-treatment. The end-use scope prominently includes hospitals, diagnostic laboratories, and research institutions investing in MRD technologies to enhance patient outcomes.

Market insights reveal that key growth factors influencing the MRD testing sector include technological advancements in molecular diagnostics, increasing prevalence of hematological cancers, and rising awareness and adoption of precision medicine. The development of sensitive, non-invasive techniques like next-generation sequencing (NGS) and polymerase chain reaction (PCR) has further expanded capabilities in detecting minute levels of residual disease. A significant potential opportunity exists in expanding MRD testing applications beyond hematological to solid tumors, which could drastically enhance its market footprint. Recommendations to capitalize on these opportunities involve developing standardized, validated, and more affordable MRD assays, along with strategic collaborations between biotech firms and research institutions for innovation acceleration.

However, market growth faces challenges such as the high cost associated with MRD testing technologies, limited accessibility in developing regions, and the need for skilled personnel to interpret complex results. Additionally, regulatory hurdles and evolving guidelines can slow down the adoption of new MRD methodologies. For growth and innovation, focusing on artificial intelligence and machine learning integration into MRD data analysis could transform result interpretation, making it more accurate and user-friendly. Ultimately, the MRD testing market is evolving rapidly, with substantial potential for growth if key barriers are addressed strategically.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Minimal Residual Disease Testing Market

The Minimal Residual Disease Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Need for refine treatment decisions for a variety of cancers
  • Rising prevalence of hematologic malignancies among world population
• Market Restraints
  • High cost associated with the MRD testing
• Market Opportunities
  • Evolution of personalized MRD testing techniques
  • Ongoing development of new minimal residual disease testing methods
• Market Challenges
  • Stringent government regulations for the commercialization of MRD

Porter's Five Forces: A Strategic Tool for Navigating the Minimal Residual Disease Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Minimal Residual Disease Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Minimal Residual Disease Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Minimal Residual Disease Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Minimal Residual Disease Testing Market

A detailed market share analysis in the Minimal Residual Disease Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Minimal Residual Disease Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Minimal Residual Disease Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Minimal Residual Disease Testing Market

A strategic analysis of the Minimal Residual Disease Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Minimal Residual Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilus Diagnostics Ltd., Amgen Inc., ARUP Laboratories, AstraZeneca PLC, Asuragen Inc. by Bio-Techne Corporation, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, C2I Genomics Inc., Cergentis B.V., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Genetron Holdings Limited, GRAIL, LLC by Illumina, Inc., Guardant Health, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., Kite Pharma, Inc. by Gilead Sciences, Inc., Laboratory Corporation of America Holdings, Mdxhealth BV, MedGenome Inc, Mission Bio, Inc., Myriad Genetics, Inc., Natera Inc., NeoGenomics Laboratories, Inc., OPKO Health, Inc., Quest Diagnostics incorporated, Sysmex Corporation, and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Minimal Residual Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Flow Cyclometry, Next-Generation Sequencing, and Polymerase Chain Reaction.
• Based on Indication, market is studied across Leukemia, Lymphoma, and Myeloma.
• Based on End-User, market is studied across Academic & Research Institutes, Diagnostic Laboratories, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Need for refine treatment decisions for a variety of cancers
    • 5.1.1.2. Rising prevalence of hematologic malignancies among world population
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with the MRD testing
  • 5.1.3. Opportunities
    • 5.1.3.1. Evolution of personalized MRD testing techniques
    • 5.1.3.2. Ongoing development of new minimal residual disease testing methods
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations for the commercialization of MRD
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Minimal Residual Disease Testing Market, by Technology

• 6.1. Introduction
• 6.2. Flow Cyclometry
• 6.3. Next-Generation Sequencing
• 6.4. Polymerase Chain Reaction

7. Minimal Residual Disease Testing Market, by Indication

• 7.1. Introduction
• 7.2. Leukemia
• 7.3. Lymphoma
• 7.4. Myeloma

8. Minimal Residual Disease Testing Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Diagnostic Laboratories
• 8.4. Hospitals

9. Americas Minimal Residual Disease Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Minimal Residual Disease Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Minimal Residual Disease Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptive Biotechnologies Corporation
• 2. Agilus Diagnostics Ltd.
• 3. Amgen Inc.
• 4. ARUP Laboratories
• 5. AstraZeneca PLC
• 6. Asuragen Inc. by Bio-Techne Corporation
• 7. Bio-Rad Laboratories, Inc.
• 8. Bristol-Myers Squibb Company
• 9. C2I Genomics Inc.
• 10. Cergentis B.V.
• 11. Exact Sciences Corporation
• 12. F. Hoffmann-La Roche Ltd.
• 13. Genetron Holdings Limited
• 14. GRAIL, LLC by Illumina, Inc.
• 15. Guardant Health, Inc.
• 16. Integrated DNA Technologies, Inc.
• 17. Invivoscribe, Inc.
• 18. Kite Pharma, Inc. by Gilead Sciences, Inc.
• 19. Laboratory Corporation of America Holdings
• 20. Mdxhealth BV
• 21. MedGenome Inc
• 22. Mission Bio, Inc.
• 23. Myriad Genetics, Inc.
• 24. Natera Inc.
• 25. NeoGenomics Laboratories, Inc.
• 26. OPKO Health, Inc.
• 27. Quest Diagnostics incorporated
• 28. Sysmex Corporation
• 29. Veracyte, Inc.